Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 4/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.58 |
| ▸ | MAPT | P10636 | 5/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.57 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.56 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.56 |
| ▸ | CACNA1I | Q9P0X4 | 2/20 | 0.56 |
| ▸ | EGFR | P00533 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | APP | P05067 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL757452 | 0.88 | STIM1 (0.61) | NPSR1LMNAKMT2ASMN1; SMN2MAPT | |
| SCHEMBL757136 | 0.84 | STIM1 (0.62) | NPSR1LMNAKMT2ASMN1; SMN2MAPT | |
| SCHEMBL758055 | 0.81 | SMN1; SMN2 (0.52) | NPSR1LMNAKMT2ASMN1; SMN2MAPT | |
| SCHEMBL758443 | 0.81 | L3MBTL1 (0.55) | NPSR1LMNASMN1; SMN2MAPTEGFR | |
| SCHEMBL3439964 | 0.81 | CACNA1G (0.64) | NPSR1LMNAKMT2ASMN1; SMN2MAPT | |
| SCHEMBL759098 | 0.81 | NPSR1 (0.54) | NPSR1LMNAKMT2ASMN1; SMN2MAPT | |
| SCHEMBL695987 | 0.80 | LMNA (0.56) | NPSR1LMNAKMT2ASMN1; SMN2MAPT | |
| SCHEMBL24336238 | 0.80 | SMN1; SMN2 (0.64) | NPSR1LMNAKMT2ASMN1; SMN2MAPT | |
| SCHEMBL758378 | 0.79 | EGFR (0.72) | NPSR1LMNAKMT2ASMN1; SMN2MAPT | |
| SCHEMBL758359 | 0.79 | LMNA (0.66) | NPSR1LMNAKMT2ASMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399436-B2 | N-pyrazolyl carboxamides as CRAC channel inhibitors | GLAXO GROUP LIMITED (GB) | 2013-03-19 | — | — | US | claimed |
| US-20120053150-A1 | N-PYRAZOLYL CARBOXAMIDES AS CRAC CHANNEL INIHIBITORS | GLAXO GROUP LIMITED (GB) | 2012-03-01 | — | — | US | claimed |
| US-8399436-B2 | N-pyrazolyl carboxamides as CRAC channel inhibitors | GLAXO GROUP LIMITED (GB) | 2013-03-19 | — | — | US | disclosed |
| US-20120053150-A1 | N-PYRAZOLYL CARBOXAMIDES AS CRAC CHANNEL INIHIBITORS | GLAXO GROUP LIMITED (GB) | 2012-03-01 | — | — | US | disclosed |
| US-20100273744-A1 | COMPOUNDS | GORE PAUL MARTIN | 2010-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053150-A1 | N-PYRAZOLYL CARBOXAMIDES AS CRAC CHANNEL INIHIBITORS | ORAI1, TRPV1, CACNA1E | NPSR1 1293/4885LMNA 857/4885KMT2A 3401/4885 |
| US-20100273744-A1 | COMPOUNDS | LTC4S, HRH4, HRH2 | NPSR1 1288/4885LMNA 4198/4885KMT2A 1734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.